Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can ...

Headquartered in Mississauga, Ontario, Diteba is exceptionally well suited to serve as the anchor laboratory for the program, supported by a robust Quality Management System and a multidisciplinary ...

Full-year 2026 revenue guidance was raised to $2.8 billion - $3 billion, assuming accelerating momentum from the branded ...

Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter ...

As chronic conditions tied to metabolic health continue to rise across the United States, MinuteClinic®, the medical clinic inside select CVS Pharmacy® locations, is highlighting its clinically ...

[Audio Gap] Diagnostics team. And for our next session, we're joined by Revvity. Pleased to be joined by Steve Willoughby, Senior VP, Investor Relations, ESG and Risk. Steve, thanks for being here.

For the last seven years, I ignored medical advice, living freely with a cholesterol at 700. Now comes the reckoning: ...

Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of ...

GLP‑1 drugs appear to change how much we want to eat, and how strongly food “pulls” on the brain. Newer oral versions may ...

NVision raises $38 million led by health diagnostics giant Abbott to scale up its groundbreaking cancer imaging system. Next ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...